Bradley Foster & Sargent Inc. CT Sells 125 Shares of Novartis AG (NYSE:NVS)

Bradley Foster & Sargent Inc. CT reduced its position in Novartis AG (NYSE:NVS) by 0.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 28,758 shares of the company’s stock after selling 125 shares during the period. Bradley Foster & Sargent Inc. CT’s holdings in Novartis were worth $2,798,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently modified their holdings of NVS. Cromwell Holdings LLC boosted its position in Novartis by 21.9% in the fourth quarter. Cromwell Holdings LLC now owns 3,918 shares of the company’s stock worth $381,000 after purchasing an additional 705 shares during the last quarter. O Brien Greene & Co. Inc lifted its stake in shares of Novartis by 2.2% in the 4th quarter. O Brien Greene & Co. Inc now owns 5,698 shares of the company’s stock worth $554,000 after purchasing an additional 124 shares during the period. Boston Financial Mangement LLC boosted its holdings in shares of Novartis by 12.8% in the fourth quarter. Boston Financial Mangement LLC now owns 9,072 shares of the company’s stock worth $883,000 after buying an additional 1,027 shares during the last quarter. Concurrent Investment Advisors LLC grew its position in Novartis by 11.0% during the fourth quarter. Concurrent Investment Advisors LLC now owns 4,143 shares of the company’s stock valued at $403,000 after buying an additional 409 shares during the period. Finally, Private Advisor Group LLC increased its holdings in Novartis by 3.8% during the fourth quarter. Private Advisor Group LLC now owns 40,522 shares of the company’s stock valued at $3,943,000 after buying an additional 1,466 shares during the last quarter. Institutional investors own 13.12% of the company’s stock.

Analyst Upgrades and Downgrades

NVS has been the subject of a number of recent research reports. Morgan Stanley started coverage on shares of Novartis in a research report on Wednesday, February 12th. They set an “underweight” rating for the company. Deutsche Bank Aktiengesellschaft upgraded Novartis from a “hold” rating to a “buy” rating in a research report on Tuesday, February 4th. HSBC cut Novartis from a “hold” rating to a “reduce” rating in a research report on Wednesday, December 4th. UBS Group reissued a “neutral” rating on shares of Novartis in a report on Thursday, February 13th. Finally, Erste Group Bank reaffirmed a “hold” rating on shares of Novartis in a report on Tuesday, November 19th. Three analysts have rated the stock with a sell rating, six have issued a hold rating, one has given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $123.38.

Novartis Trading Up 2.0 %

NVS stock opened at $109.42 on Friday. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.04 and a quick ratio of 0.84. Novartis AG has a 1-year low of $92.35 and a 1-year high of $120.92. The business has a 50 day simple moving average of $101.24 and a two-hundred day simple moving average of $108.15. The company has a market capitalization of $223.65 billion, a price-to-earnings ratio of 18.61, a PEG ratio of 1.70 and a beta of 0.58.

Novartis (NYSE:NVS) last issued its earnings results on Friday, January 31st. The company reported $1.98 earnings per share for the quarter, topping analysts’ consensus estimates of $1.80 by $0.18. Novartis had a net margin of 23.56% and a return on equity of 37.24%. Research analysts anticipate that Novartis AG will post 8.45 EPS for the current fiscal year.

About Novartis

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.